CL2021003170A1 - Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa - Google Patents
Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasaInfo
- Publication number
- CL2021003170A1 CL2021003170A1 CL2021003170A CL2021003170A CL2021003170A1 CL 2021003170 A1 CL2021003170 A1 CL 2021003170A1 CL 2021003170 A CL2021003170 A CL 2021003170A CL 2021003170 A CL2021003170 A CL 2021003170A CL 2021003170 A1 CL2021003170 A1 CL 2021003170A1
- Authority
- CL
- Chile
- Prior art keywords
- histone deacetylase
- methods
- deacetylase inhibitors
- associated cancers
- treating virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En el presente documento se describen ciertos montos y calendarios de dosificación que evitan y gestionan de manera eficaz los efectos colaterales asociados con el tratamiento con inhibidores de la histona deacetilasa. Opcionalmente, estos calendarios y regímenes de dosificación incluyen tratamiento con un agente antiviral.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962855454P | 2019-05-31 | 2019-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021003170A1 true CL2021003170A1 (es) | 2022-07-15 |
Family
ID=73552282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021003170A CL2021003170A1 (es) | 2019-05-31 | 2021-11-29 | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa |
Country Status (5)
Country | Link |
---|---|
AR (1) | AR119033A1 (es) |
CL (1) | CL2021003170A1 (es) |
TW (1) | TW202110452A (es) |
UY (1) | UY38720A (es) |
WO (1) | WO2020243326A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020395837A1 (en) | 2019-12-05 | 2022-06-16 | Viracta Subsidiary, Inc. | HDAC inhibitor solid state forms |
EP4237409A1 (en) | 2020-10-28 | 2023-09-06 | Viracta Subsidiary, Inc. | Hdac inhibitor solid state forms |
WO2024086688A1 (en) * | 2022-10-21 | 2024-04-25 | Viracta Subsidiary, Inc. | Dosing methods for hdac inhibitor compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016014484A1 (en) * | 2014-07-21 | 2016-01-28 | The Rockefeller University | Combination of broadly neutralizing hiv antibodies and viral inducers |
EP3310168A4 (en) * | 2015-06-19 | 2019-03-06 | Trustees of Boston University | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS INDUCED BY HERPETIC VIRUS |
-
2020
- 2020-05-28 TW TW109117909A patent/TW202110452A/zh unknown
- 2020-05-28 AR ARP200101512A patent/AR119033A1/es unknown
- 2020-05-28 UY UY0001038720A patent/UY38720A/es unknown
- 2020-05-28 WO PCT/US2020/034951 patent/WO2020243326A1/en unknown
-
2021
- 2021-11-29 CL CL2021003170A patent/CL2021003170A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
UY38720A (es) | 2020-12-31 |
WO2020243326A1 (en) | 2020-12-03 |
AR119033A1 (es) | 2021-11-17 |
TW202110452A (zh) | 2021-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021003170A1 (es) | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa | |
CL2023000847A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
DOP2020000209A (es) | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t | |
CL2018000853A1 (es) | Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer. | |
ECSP18094983A (es) | Derivados de pirazol como inhibidores de la calicreína plasmática | |
CL2017002494A1 (es) | Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer | |
BR112018073328A2 (pt) | combinação, composição farmacêutica, kit, método para tratamento de câncer, método para a redução de um nível de células, método para reduzir o nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade | |
EA201992220A1 (ru) | Комбинированная терапия для лечения или предупреждения опухолей | |
MX2017000307A (es) | Tratamiento de leucemia con inhibidores de histona deacetilasa. | |
PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
EA201890567A1 (ru) | Способ лечения рака | |
MX2020004179A (es) | Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso. | |
MX2020004837A (es) | Inhibidores de la vía de adenosina para el tratamiento del cáncer. | |
BR112018008882A2 (pt) | método para tratar um distúrbio proliferativo e produto farmacêutico | |
BR112019003533A2 (pt) | terapia de combinação com inibidores de glutaminase | |
BR112018071031A2 (pt) | combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr | |
AR119934A1 (es) | Inhibidores de pikfyve para terapia contra el cáncer | |
BR112017018198A2 (pt) | inibição da atividade de olig2 | |
NI202000052A (es) | Terapia de combinación para tratar o prevenir el cáncer | |
CL2022001458A1 (es) | Método para el tratamiento de cáncer utilizando célula ad-yuvante artificial (aavc) | |
BR112017014914A2 (pt) | terapia combinada para hipertensão pulmonar | |
CL2021001096A1 (es) | Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196) | |
MX2021014639A (es) | Metodos para tratar canceres asociados con virus con inhibidores de la histona deacetilasa. | |
CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. |